Study supports cost-effectiveness of wider HCV screening

Screening adults between the ages of 20 and 69 for hepatitis C would be cost-effective when compared with the costs of managing late-stage liver fibrosis, University of Washington researchers reported. They said risk-factor-based screening has missed at least half of HCV cases, so that 25% of people newly diagnosed with the disease already have cirrhosis of the liver. (3/14)